EBS Emergent BioSolutions PE ratio, current and historical analysis
The current price-to-earnings ratio of EBS can't be determined, as the TTM EPS of -$3.93 is negative. The last PE ratio of Emergent BioSolutions, recorded in September 2022, was 56.73.
EBS PE ratio history
The PE ratio of Emergent BioSolutions has averaged 49.66 over the last ten years. In the past ten years, EBS's PE ratio peaked in the Sep 2019 quarter at 746.86, when the stock price was $52.28 and the EPS was $0.07. The lowest point was in the Dec 2021 quarter, when it reached 10.6 with a price of $43.47 and an EPS of $4.1.
Emergent BioSolutions PE ratio by year
Maximum annual increase: 102.05% in 2018
Maximum annual decrease: -69.65% in 2020
| Year | PE ratio | Change |
|---|---|---|
| 2023 | N/A | N/A |
| 2022 | N/A | N/A |
| 2021 | 10.6 | -31.39% |
| 2020 | 15.45 | -69.65% |
| 2019 | 50.9 | 7.34% |
| 2018 | 47.42 | 102.05% |
| 2017 | 23.47 | -7.82% |
| 2016 | 25.46 | 3.71% |
| 2015 | 24.55 | -11.66% |
| 2014 | 27.79 | 3.97% |
EBS average PE ratio chart
EBS PE vs peers
| Stock name | PE ratio | Market cap |
|---|---|---|
| SIGA Siga Technologies Inc | 4.93 | $422M |
| MRK Merck & Co Inc | 20.47 | $248.03B |
| PFE Pfizer Inc | 34.68 | $149.38B |
| CMRX Chimerix Inc | N/A | $268.91M |
| XOMA XOMA Corp | N/A | $319.67M |
| CLDX Celldex Therapeutics Inc | N/A | $1.67B |
| TEVA Teva Pharmaceutical Industries Ltd | N/A | $25.03B |
| EBS Emergent BioSolutions Inc | N/A | $438.89M |
Frequently asked questions
What is Emergent BioSolutions's PE ratio?
The current price to earnings ratio of EBS can't be calculated, as its EPS of -$3.93 is negative.
What is the 5-year average PE ratio for Emergent BioSolutions (EBS)?
As an average over the last 5 years, EBS stock has a PE ratio of 25.4.
What is the highest PE ratio for EBS?
The highest quarterly PE ratio in the last ten years has been 746.86 and it was in the Sep 2019 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from 
and Sharadar.